Corrections to Successful engineering cancer immunotherapy [Eur. J. Immunol. 44, 02 (2014)] doi: 10.1002/eji.201444472;Successful engineering cancer immunotherapy

European Journal of Immunology

Volumn 44, Issue 2, 2014, Pages 318-320

  Romero, Pedro ^a   Coukos, George ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BCG VACCINE; CANCER VACCINE; CD19 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; BLADDER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; CHIMERA; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; KIDNEY CELL; LYMPHOCYTE TRANSFER; MELANOMA; MYCOBACTERIUM BOVIS BCG; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NOTE;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84893530443     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201470027     Document Type: Erratum

References (28)

1. Coley, W. B. et al., Am. J. Med. Sci. 1893. 105: 487-511.
2. Atkins, M. B. et al., J. Clin. Oncol. 1999. 17: 2105-2116.
3. Grunhagen, D. J. et al., Nat. Clin. Pract. Oncol. 2006. 3: 94-103.
4. Brincks, E. L. et al., Semin. Cancer. Biol. 2013. 23: 183-189.
5. DuPage, M. et al., Cancer Cell. 2011. 19: 72-85.
6. Schreiber, R. D. et al., Science 2011. 331: 1565-1570.
7. Galon, J. et al., Immunity 2013. 39: 11-26.
8. Gu-Trantien, C. et al., J. Clin. Invest. 2013. 123: 2873-2892.
9. DeNardo, D. G. et al., Cancer Cell. 2009. 16: 91-102.
10. Qian, B. Z. et al., Nature 2011. 475: 222-225.
11. Bukur, J. et al., Semin. Cancer 2012. 22: 350-358.
12. Finn, O. J., Ann. Oncol. 2102. 32(Suppl 8) viii6-9.
13. Restifo, N. P. et al., Nat. Rev. Immunol. 2012. 12: 269-281.
14. Barrett, D. M. et al., Annu. Rev. Med. 2014. 65: 333-347.
15. Grupp, S. A. et al., New Engl. J. Med. 2013. 368: 1509-1518.
16. Morgan, R. A. et al., J Immunother. 2013. 36: 133-151.
17. Morgan, R. A. et al., Mol. Ther. 2010. 18: 843-851.
18. Kantoff, P. W. et al., New Engl. J. Med. 2010. 363: 411-422.
19. Braun, M. et al., Eur. J. Immunol. 2012. 42: 330-340.
20. Pardoll, D. M., Nat. Rev. Cancer 2012. 12: 252-264.
21. van Elsas, A. et al., J. Exp. Med. 1999. 190: 355-366.
22. Hodi, F. S. et al., New Engl. J. Med. 2010. 363: 711-723.
23. Brahmer, J. R. et al., New. Eng. J. Med. 2012. 366: 2455-2465.
24. Topalian, S. L. et al., New Engl. J. Med. 2012. 366: 2443-2454.
25. Wolchok, J. D. et al., New Engl. J. Med. 2013. 369: 122-133.
26. Couzin-Frankel, J., Science 2013. 342: 1432-1423.
27. Robbins, P. F. et al., Nat. Med. 2013. 19: 747-752.
28. Wick, D. A. et al., Clin. Cancer Res. 2013. DOI: 10.1158/1078-0432.CCR-13-2147.